Rev. Add2

Schema



N = 660

Cycle = Step 1 (Arms A & B): 28 days for patients receiving platinum doublet option #1 (see below)
21 days for patients receiving platinum doublet option #2 (see below)
7 days for patients receiving platinum doublet option #3 (see below)
Step 2 (Arm C): 28 days for patients on consolidative durvalumab (Arm C).

1. Investigator's Choice for Step 1 (see Section 5.1):
   a. Option #1: Cisplatin 50 mg/m2 IV on C1D1, C1D8, C2D1, C2D8; Etoposide 50 mg/m2 IV C1D1-D5; C2D1-D5 (Cycle = 28 days)
   b. Option #2: Pemetrexed 500 mg/m2 IV C1D1, C2D1; Cisplatin 75 mg/m2 IV on C1D1, C2D1 (Cycle = 21 days) (nonsquamous only)
   c. Option #3: Paclitaxel 45 mg/m2 IV on D1 of each cycle for 6 cycles; Carboplatin AUC 2 IV on D1 of each cycle for 6 cycles (Cycle = 7 days)